SCHEMBL2230718

SCHEMBL2230718

COc1ccc2cc(-c3ccccc3)c(C(=O)C(=O)Nc3ccc(N4CCN(c5cc(C)cc(C)n5)CC4)cc3)n2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
USP2 O75604 2/20 0.44
SLC1A2 P43004 1/20 0.42
MAPT P10636 5/20 0.41
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
GFER P55789 1/20 0.40
PHGDH O43175 1/20 0.40
KDM4E B2RXH2 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TSHR P16473 3/20 0.39
HSD17B10 Q99714 2/20 0.38
TP53 P04637 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DRD4 P21917 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
GALR2 O43603 1/20 0.37
GALR1 P47211 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647365 0.98 LMNA (0.43) LMNAUSP2SLC1A2MAPTALDH1A1
SCHEMBL1646567 0.92 SLC1A2 (0.43) LMNAUSP2SLC1A2MAPTALDH1A1
SCHEMBL1646659 0.91 MAPT (0.43) LMNAUSP2MAPTALDH1A1HTT
SCHEMBL1646592 0.89 SLC1A2 (0.42) LMNAUSP2SLC1A2MAPTALDH1A1
SCHEMBL2230023 0.89 MAPT (0.42) LMNAUSP2MAPTALDH1A1HTT
SCHEMBL1646439 0.89 MAPT (0.42) LMNAUSP2MAPTALDH1A1HTT
SCHEMBL1644596 0.89 MAPT (0.44) LMNAUSP2MAPTALDH1A1HTT
SCHEMBL1648138 0.87 MAPT (0.53) LMNAUSP2MAPTALDH1A1HTT
SCHEMBL2232419 0.87 MAPT (0.40) LMNAUSP2MAPTALDH1A1HTT
SCHEMBL1646568 0.87 LMNA (0.47) LMNASLC1A2MAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 LMNA 3870/4885USP2 4733/4885SLC1A2 724/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 LMNA 1805/4885USP2 3475/4885SLC1A2 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.